ClinicalTrials.gg
RecruitingNCT07733089Updated Jul 29, 2026

A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period

A Phase 1 interventional study of ZP9830 and Placebo in Plaque Psoriasis, sponsored by Zealand Pharma. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Zealand Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 65 studies in Psoriasis with a site in Netherlands — 5 open to participants now, 8 under way, 1 of them phase 3. Psoriasis · Netherlands.

Planned enrollment
48th of 50
32 · median 276
Started
2026
with 1 other
Phase 1
2 of 65
2 open now
Registered
64th of 65
by date

Among the 65 studies in Psoriasis with a site in Netherlands, this one is the 48th largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1, and was the 64th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 65 studies in Psoriasis with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Psoriasis with a site in Netherlands, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a confirmed diagnosis of psoriasis (stable plaque psoriasis ≥ 2 months).
  • Participants who have ≥ 2 vulgar psoriatic plaques.
  • within the range 18.0-35.0 kg/m2 (inclusive).
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Erythrodermic, predominantly guttate, exclusively palmar/plantar, or generalized pustular psoriasis.
  • Current drug-induced or aggravated psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium-channel blockers, or lithium carbonate).
  • Any abnormalities, as judged by the investigator, in laboratory test results (including hematology, biochemistry, and urinalysis).
  • Any clinically significant abnormal findings during the standardized neurological examination conducted at screening.
  • Use of any concurrent systemic medications that could affect psoriasis or psoriasis evaluation, including , retinoids, cyclosporine, methotrexate, PDE4s (phosphodiesterase 4), or biologic agents within 30 days prior to IMP administration or planned to use during the course of the trial.
  • Use of concurrent topical medications containing corticosteroids, retinoids, calcitriol or other topical medication relevant to psoriasis treatment (must be discontinued at least 2 weeks prior to baseline).
  • Use of any biologic or advance systemic therapies for any disease within the last 12 months.
  • Use of UVA, PUVA, or UVB therapy and tanning beds within 4 weeks of baseline or during trial participation.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    ZP9830

    The experimental arm is divided into two treatment arms with different dose frequencies.

    Drug: ZP9830

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugZP9830

    Participants will receive multiple doses of ZP9830. The dose frequency will depend on treatment arm

  • DrugPlacebo

    Participants will receive multiple doses of placebo

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs)

    To evaluate the safety and tolerability of ZP9830 following administration of multiple doses in participants with plaque psoriasis.

    Time frame: From baseline (Day 1, predose) to follow-up (Day 85)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 9 months is close to that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jul 29, 2026
StartActual
Jul 22, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07733089
Lead sponsor
Zealand Pharma
Collaborators
Centre for Human Drug Research, Netherlands, ICON Clinical Research
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jul 22, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Clinical Operations
Contact
clinicaltrials@zealandpharma.com
+45 88 77 36 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion